Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2012: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2011: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
Research Abstract |
I found that ER ligands suppress tumor angiogenesis of androgen independent prostate cancer through novel non-genomic pathway of ERβ, and thereby inhibit tumor growth. Moreover, I also found that NFκB is novel target gene of ERβ non-genomic pathway, and identified some inhibitory compounds of NFκB activity. These findings may provide a suitable target for androgen independent prostate cancer treatment.
|